A liposomal composition ('ADx-003') is provided, ADx-003 comprising a first phospholipid; a sterically bulky excipient that is capable of stabilizing the liposomal composition; a second phospholipid that is derivatized with a first polymer; a macrocyclic gadolinium-based imaging agent; and a third phospholipid that is derivatized with a second polymer, the second polymer being conjugated to a targeting ligand, the targeting ligand being represented by Formula (I): wherein X is -CH2-, -CH2-CH2-, -CHO-, or -O-CO-; Y is -CH-CH=CH- or (II); A and B are independently selected from C and N; R1, R2, R3, and R4 are independently selected from - H, halogen, -OH, and -CH3; and R5, R6, and R7 are independently selected from -H, halogen, -OH, -OCH3, -NO2, -N(CH3)2, C1-C6 alkyl, or a substituted or unsubstituted G4-C6 aryl group, except that when A and/or B is N the adjacent R5 and/or R7 is -H, or a pharmaceutically acceptable salt thereof.
TARGETED CONTRAST AGENTS FOR MRI OF ALPHA-SYNUCLEIN DEPOSITION